he'll either go on to do it all again (caveat emptor) or retire to his (ok, not his) mansion - yet another case study on the lack of effective oversight on the ASX IMHO
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%